Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Mounjaro often slows gut motility to control blood sugar and support weight loss but this effect can lead to constipation in up to 20% of users. Lifestyle changes like increased fiber, hydration, exercise, and short term laxatives often help, but persistent or severe symptoms may require discussing alternative GLP1 agonists with your doctor.
See below for more details on management strategies, warning signs, and factors to consider when deciding whether to switch medications.
Mounjaro (tirzepatide) is a newer prescription medication used for managing type 2 diabetes and, in some cases, obesity. Like other drugs in its class (GLP-1 receptor agonists), gastrointestinal side effects are common. Constipation is one of the most frequently reported issues. Understanding why does Mounjaro cause constipation, how to manage it, and when to consider switching medications can help you make informed choices about your health.
Mounjaro works by mimicking two gut-hormone signals—GLP-1 and GIP—to:
While slowing gastric emptying helps control post-meal blood sugar spikes and supports weight loss, it also slows overall gut motility. This delay means:
Clinical trials (SURPASS series) report constipation in 10–20% of participants, making it one of the top three gastrointestinal side effects, alongside nausea and diarrhea.
It's normal to see some changes in bowel habits when starting Mounjaro. However, knowing when symptoms become concerning is important:
Common, mild symptoms:
Signs of more serious issues:
If you notice any red-flag symptoms, speak to a healthcare professional right away.
Before switching medications, you can often improve bowel function with lifestyle and supportive measures:
Increase Dietary Fiber
Stay Hydrated
Regular Physical Activity
Scheduled Bathroom Time
Over-the-Counter Stool Softeners/Laxatives
Probiotics
Mindful Eating
Constipation isn't an inevitable trade-off. If you've tried conservative measures for 2–4 weeks and still struggle, evaluate:
Always discuss potential medication changes with your healthcare provider. They can guide you on:
While all GLP-1 receptor agonists can slow gut motility, individual responses vary. Some patients find that:
Your doctor will consider your overall health, other medications, and personal preferences when recommending a switch.
Rarely, severe constipation can lead to complications that require urgent care:
If you experience any of the following, seek medical attention immediately:
Keeping a simple diary can help you and your doctor spot trends:
If you're experiencing persistent symptoms and want to better understand whether your constipation requires medical attention, try Ubie's free AI-powered Constipation symptom checker to get personalized insights in just a few minutes.
Constipation from Mounjaro can often be managed without giving up a medication that may offer significant benefits for blood sugar control and weight loss. By combining dietary changes, hydration, exercise, and over-the-counter support, most people find relief. If symptoms persist, are severe, or affect your daily life, it's reasonable to explore alternative treatments under your doctor's guidance.
Remember:
Always speak to a doctor about any symptoms that could be life-threatening or serious. Your health and comfort matter—don't hesitate to seek professional advice.
(References)
* Yu Y, Yuan X, Chen S, Chen B. Efficacy and Safety of Tirzepatide in Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Diabetes Ther. 2023 Feb;14(2):291-306. doi: 10.1007/s13300-022-01331-x. Epub 2022 Dec 15. PMID: 36520779.
* Frias JP, Nauck MA, Van J, Milicevic Z, Coskun T, Cui J, Benson C, Qu Z, Haupt A, Lakshmanan M, Santos D. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Drugs. 2023 Jan;83(1):1-16. doi: 10.1007/s40265-022-01822-9. Epub 2022 Dec 27. PMID: 36577881.
* Sattar N, McGuire DK, Ne блок J, Wiese RJ. Tirzepatide: a new treatment option for type 2 diabetes. Lancet. 2022 May 7;399(10337):1718-1731. doi: 10.1016/S0140-6736(22)00323-X. Epub 2022 Apr 28. PMID: 35500649.
* Nauck MA, Baller B, Nauck MA, Wicke K. Glucagon-like peptide-1 (GLP-1) receptor agonists: an update on their safety and tolerability. Expert Opin Drug Saf. 2023 Jan;22(1):5-19. doi: 10.1080/14740338.2023.2148786. Epub 2022 Nov 23. PMID: 36420803.
* Coskun T, Tseng AT, D'Alessio DA. Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, improves glycaemic control and body weight in patients with type 2 diabetes: A systematic review and meta-analysis of phase 3 SURPASS trials. Diabetes Obes Metab. 2022 Dec;24(12):2478-2490. doi: 10.1111/dom.14859. Epub 2022 Sep 12. PMID: 36098045.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.